Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GLUTAMIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,621 records · Page 90Linked to original sources
PubMed2005

Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier.

The objective of the present study was to prepare nanoparticles composed of poly(gamma-glutamic acid) (gamma-PGA) and l-phenylalanine ethylester (l-PAE) in order to evaluate the possibility of using these nanoparticles as protein carriers. Novel amphiphilic graft copolymers composed of gamma-PGA as the hydrophilic backbone and l-PAE as the hydrophobic segment were successfully synthesized by grafting l-PAE to gamma-PGA using water-soluble carbodiimide (WSC). Due to their amphiphilic properties, the gamma-PGA-graft-l-PAE copolymers were able to form nanoparticles. The size of the gamma-PGA nanoparticles was measured by photon correlation spectroscopy (PCS) and showed a monodispersed size distribution with a mean diameter ranging from 150 to 200 nm. The solvents selected to prepare the gamma-PGA nanoparticles by a precipitation and dialysis method affected the particle size distribution. To evaluate the feasibility of vehicles for these proteins, we prepared protein-loaded gamma-PGA nanoparticles by surface immobilization and encapsulation methods. Ovalbumin (OVA) was used as a model protein and was immobilized onto the gamma-PGA nanoparticles or encapsulated into the inner core of these nanoparticles. Moreover, these OVA-encapsulated gamma-PGA nanoparticles could be preserved by freeze-drying process. The results of cytotoxicity tests showed that the gamma-PGA and gamma-PGA nanoparticles did not cause any relevant cell damage. It is expected that biodegradable gamma-PGA nanoparticles can immobilize proteins, peptides, plasmid DNA and drugs onto their surfaces and/or into the nanoparticles. These nanoparticles are potentially useful in pharmaceutical and biomedical applications.

Cell Proliferation↗
PubMed1985

The time of origin of cells demonstrating glutamic acid decarboxylase-like immunoreactivity in the hippocampal formation of the rat.

Using the combination of [3H]thymidine autoradiography and immunohistochemistry for the detection of glutamic acid decarboxylase (GAD), we have determined that most of the cells demonstrating GAD-like immunoreactivity in the hippocampal formation of the rat become postmitotic on fetal day 14, though some cease dividing on fetal days 13 and 15-18. GAD-positive cells in all fields of the hippocampal formation appear to differentiate during roughly the same period though there is evidence for both septotemporal and regional variations in the pattern of development.

Animals↗
PubMed1995

Helix formation of poly (L-glutamic acid) in the presence of alkaline earth metal cations in aqueous alcohol solutions.

Effects of divalent counterions (Mg2+, Ca2+, Sr2+, Ba2+) on the helix formation of poly(L-glutamic acid) are investigated in aqueous alcohol (MeOH, EtOH, 2PrOH, tBuOH) solutions. To observe helix formation inherent to the divalent counterions, the chlorides were added to a poly(L-glutamate) having an inert monovalent counterion, tetrabutylammonium cation. Marked counterion- and alcohol-specificities were observed for the dependence of helix content, theta, on the alcohol content. The theta values for most Mg2+ and Ca2+ systems decreased with increasing alcohol content in a higher alcohol region, while those for Sr2+ and Ba2+ systems were almost constant. A specific helix stabilization was observed for mixed divalent counterion systems. These results are self-consistently interpreted by taking into account contact ion-pair formation between the counterions and the polymer charges on the coil conformation.

Alcohols↗
PubMed1997

Ontogeny of glutamic acid decarboxylase gene expression in the mouse pancreas.

Using two RT-PCR quantitative assays, we measured the pancreatic expression of the two isoforms of glutamic acid decarboxylase in the foetus, newborn and 14-, 21- and 35-day-old male and female NOD and C57BL/6 mice. In the C57BL/6 mouse, GAD 67 pancreatic expression is stable; in NOD mice, GAD 67 expression is similar to that found in control mice, except at 5 weeks of age, when pancreatic GAD 67 expression is about 2.5 times higher than in C57BL/6 mice. The pancreatic expression of GAD 65 is under the detection limit of the assay until 5 weeks of age. The overexpression of GAD 67 characterized in pancreas from 5-week-old NOD mice could be the result of beta cell hyperactivity, previously reported in this mouse strain.

Animals↗
PubMed1986

Glutamic acid decarboxylase (GAD) immunocytochemistry of developing rabbit hippocampus.

Immunocytochemical techniques were used to examine the synaptic relations of inhibitory interneurons in the developing rabbit hippocampus. Glutamic acid decarboxylase (GAD), the synthesizing enzyme for the inhibitory neurotransmitter GABA, was found in interneurons of immature (8 d old) as well as mature (30 d old) tissue. GAD-immunoreactivity was seen in somata, dendrites, and axon terminals of interneurons at both ages. Electron-microscopic examination revealed that GAD-positive "terminals" in immature tissue were often not associated with the usual synaptic specializations, but were rather in simple apposition to the "postsynaptic" element. In mature tissue, GAD-positive terminals made symmetric contacts primarily with pyramidal cell somata, initial segments, and proximal dendrites. In addition, GAD-positive terminals synapsed onto both GAD-positive and GAD-negative interneuron profiles.

Animals↗
PubMed1985

Glutamic acid decarboxylase immunoreactivity in layer IV of barrel cortex of rat and mouse.

The morphology and distribution of neurons and terminals that are immunoreactive to glutamic acid decarboxylase (GAD) were investigated in barrel cortex of the rat and mouse. The morphology of the GAD-immunoreactive neurons located in layer IV of the barrel field resembles that of the large, smooth stellate neurons described previously in Golgi studies. Most of the somas of GAD-positive neurons are located along the sides of the barrels. They constitute about 13 to 15% of the total neuronal population in layer IV. The spatial distribution of GAD-positive terminals in layer IV is similar to the distribution of GAD-positive somas. Very few GAD-positive neurons and terminals are found in the septal regions. This unique distribution of GAD immunoreactivity in the barrel cortex may serve as a model to study cortical inhibitory mechanisms.

Animals↗
PubMed1980

Inactivation of mutagens from pyrolysates of tryptophan and glutamic acid by nitrite in acidic solution.

The mutagenic aromatic amines Trp-P-1, Trp-P-2 and Glu-P-1, isolated frm pyrolysates of tryptophan and glutamic acid, at the concentration of 0.025 mM were treated with 0.05 mM nitrite at various pH values at 37 degrees C. The resulting reaction mixtures were tested for mutagenicity towards Salmonella typhimurium TA98 and TA100. When treated with nitrite at this physiologically realistic concentration, these mutagenic aromatic amines were readily converted to extremely weak or non-mutagenic deaminated compounds. These deaminated products were identified as the corresponding hydroxy compounds by mass and proton magnetic resonance spectroscopies. Comparative kinetic studies were made on the disappearance of the mutagenic aromatic amines. The half-life (t1/2 of Glu-P-1 on treatment with nitrite at pH 1.6 was less than 5 min, and those of Trp-P-1 and Trp-P-2 were 95 and 105 min, resp.

Amines↗
PubMed1994

Analysis of the anatomical distribution of GAD67 mRNA encoding truncated glutamic acid decarboxylase proteins in the embryonic rat brain.

During development of the central nervous system (CNS) the gene that encodes the 67 kDa form of glutamic acid decarboxylase (GAD) undergoes alternative splicing. The alternatively spliced variants include an exon (referred to as ES, for embryonic stop) that contains a premature stop codon. The detection of mRNA containing the ES exon in embryonic rat brain has been previously reported (Proc. Natl. Acad. Sci., 87 (1990) 8771-8775). We have used in situ hybridization to identify the anatomical distribution of ES mRNA in the embryonic rat brain during two stages of development, embryonic day 17 (E17) and E20. At E17, GAD67 mRNA was expressed in several CNS regions that were destined to contain GABAergic neurons when mature. ES transcripts were predominantly localized to ventricular zones and other regions associated with populations of proliferative cells at E17 and E20. At both ages, however, the alternatively spliced variants were also detected in regions of brain associated with migratory or post-mitotic neurons. GAD67 transcripts that did not include the ES exon were localized to anatomical areas that contained post-mitotic, and often post-migratory neurons. The temporal and spatial disappearance of mRNA containing the ES exon generally followed a caudal-to-rostral gradient which paralleled neuronal terminal mitosis and differentiation.

Animals↗
PubMed1997

Comparison of a new anti-glutamic acid decarboxylase (GAD) enzyme-linked immunosorbent assay (ELISA) with radioimmunoassay methods: a multicenter study.

Several methods are available for the measurement of antibodies to glutamic acid decarboxylase (anti GAD). These antibodies are valuable tools for the immunodiagnosis of insulin-dependent (type 1) diabetes mellitus (IDDM) and for the assessment of risk for the future development of IDDM. We here describe a new enzyme-linked immunosorbent assay (ELISA) for the detection of anti-GAD which was tested in a multicenter study. The results of the new anti-GAD ELISA correlate well with those obtained by radioimmunoassays (RIA) and they have a higher sensitivity (69%) and specificity (98%) compared to other anti-GAD enzyme immunoassays as determined in the IDW Proficiency Test Program for the detection of GAD antibodies. The new ELISA is simple and easy to perform, with convenient handling of the reagents. Quantitative and reproducible test results are available within approximately four hours. The new anti-GAD ELISA can be used for large scale population screening to indicate a prediabetic state as well as to diagnose autoimmune diabetes in adults (LADA) and the risk for IDDM in pregnant women with gestational diabetes.

Adult↗
PubMed1996

Radioimmunoprecipitation assay for glutamic acid decarboxylase antibodies evaluated clinically with sera from patients with insulin-dependent diabetes mellitus.

We evaluated a new, commercially developed radioimmunoprecipitation assay for measuring glutamic acid decarboxylase (GAD) antibodies by using recombinant human GAD65. The intra- and interassay CVs were 8.0% (n = 20) and 8.6% (n = 15), respectively. We found GAD antibodies in 74% (23 of 31; 95% confidence interval 55-88%), 70% (14 of 20; 46-88%), and 65% (28 of 43; 49-79%) of patients at, respectively, < or = 1 year, 1-2 years, and 2-4 years after the onset of insulin-dependent diabetes mellitus (IDDM) and in 30% (30 of 99; 21-40%) of patients with long-term diabetes (4-22 years). We also detected GAD antibodies in 8% (9 of 106; 4-16%) of patients with non-insulin-dependent diabetes mellitus (NIDDM). The frequency of GAD antibodies in the NIDDM group was markedly higher in the insulin-deficient patients [67% (6 of 9; 30-93%)], who initially were nonketotic and non-insulin-dependent for > or = 6 months but later became insulin dependent, than in the non-insulin-deficient patients [3% (3 of 97; 1-9%)]. This new commercial assay is easy to use and provides a specific and sensitive method for evaluating GAD antibodies in IDDM.

Adolescent↗
PubMed1989

Demonstration of GABAergic cell bodies in the suprachiasmatic nucleus: in situ hybridization of glutamic acid decarboxylase (GAD) mRNA and immunocytochemistry of GAD and GABA.

The existence of GABAergic neurons in the rat suprachiasmatic nucleus (SCN) was demonstrated by three specific markers; mRNA coding for glutamic acid decarboxylase (GAD) and visualized by in situ hybridization using a 35S-labelled cDNA probe, and GAD protein and GABA were identified by immunocytochemistry using specific antisera. In situ hybridization demonstrated well labelled GAD mRNA positive cells throughout SCN, and GABA and GAD immunoreactive cells showed similar distributions. These results indicate that GABA is a transmitter of a large portion of the SCN neuronal population.

Animals↗
PubMed1997

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.

BACKGROUND: Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables. METHODS: We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 white patients with type 2 diabetes, aged between 25 and 65 years. The phenotype was assessed by age of onset, body-mass index, percentage haemoglobin A1c (HbA1c), and islet beta-cell function. We investigated the need for insulin therapy among 1538 patients not assigned insulin and followed up for 6 years from diagnosis. FINDINGS: The proportion of patients with ICA and GADA decreased with increasing age at diagnosis (from 33 [21%] of 157 patients aged 25-34 [corrected] to 66 [4%] of 1769 aged 55-65 for ICA; from 53 [34%] to 122 [7%] for GADA). Among patients younger than 35 at diagnosis, those with ICA or GADA had lower body-mass index than those without (mean 24.9 [SD 6.0] vs 31.7 [7.3] kg/m2; p < 0.0001 and had higher percentage of HbA1c (9.7 vs 8.7%, p < 0.05). 94% of patients with ICA and 84% of those with GADA required insulin therapy by 6 years, compared with 14% of those without the antibodies (p < 0.0001). Among patients older than 55 at diagnosis, the difference between those with and without antibodies in body-mass index was smaller (27.2 [5.4] vs 28.6 [4.8] kg/m2, p < 0.001); 44% of those with ICA, 34% of those with GADA, and 5% with neither antibody required insulin therapy by 6 years (p < 0.0001). Among patients older than 45 years, body-mass index and HbA1c provided little predictive information for insulin requirement, whereas the positive predictive values of GADA (> or = 60 U/L) alone, or both GADA (> or = 20 U/L) and ICA (> 5 U/L), for insulin therapy were 52% and 68%. INTERPRETATION: Among young adults with type 2 diabetes, the phenotype of those with ICA or GADA antibodies was similar to that of classic juvenile-onset insulin-dependent diabetes, and either phenotype or antibodies predicted insulin requirement. In older adults, the phenotype was closer to that of patients without antibodies and only the presence of antibodies predicted an increased likelihood of insulin requirement.

Adult↗
PubMed1975

Genetic control of the murine cell-mediated immune response in vivo. I. H-2-linked responsiveness to the terpolymer L-glutamic acid-60-L-alanine-30-L-tyrosine-10.

Various inbred and congenic strains of mice were immunized with the linear terpolymer L-glutamic acid-60-L-alanine-30-L-tyrosine-10 (GAT). Using a radioisotopic footpad assay to measure cell-mediated immunity in vivo, mice with H-2-a, H-2-b, H-2-d, and H-2-k histocompatibility alleles showed a positive reaction, whereas mice with H-2p and H-2-s alleles failed to respond. The ability of "responder" lymphocytes to show an immune response resides in the thymus-derived (T) lymphocyte population. Unfractionated spleen cells from H-2-q nonresponder mice, on transfer, showed no reactivity, whereas T-cell-enriched preparations were active.

Alanine↗